ICH E6 R3 Changes: What Is New Compared With R2

ICH E6(R3) is the revised Good Clinical Practice guideline that replaces E6(R2). The main ich e6 r3 changes are a risk-based, proportionate approach, explicit recognition of centralised monitoring and remote access, a focus on critical data and processes, and wider scope for decentralised and digitally enabled trials.
If you are searching for ich e6 r3 changes, the short answer is that R3 moves monitoring away from a site-visit-centred model toward a risk-based, fit-for-purpose model. This article compares the two versions, explains where R3 applies, and sets out what it means for monitors and sites.
What changed in ICH E6(R3) compared with R2?
The gcp r3 vs r2 comparison is clearest in the monitoring and quality control sections. R3 keeps the ethical and quality foundations of R2 but describes monitoring as a set of activities that can combine on-site, remote and centralised methods [1].
Build These Skills Now
Programs from ZANE ProEd Academy that directly address the skill gaps discussed above.
| Topic | ICH E6(R2) | ICH E6(R3) |
|---|---|---|
| Overall approach | Quality by design and risk proportionate, with monitoring largely framed around site visits | Explicit risk-based, fit-for-purpose quality management across the trial lifecycle |
| Monitoring methods | On-site monitoring is the reference model | Monitoring may be on-site and/or remote, and may include centralised monitoring [1] |
| Centralised monitoring | Not described as a distinct method | Defined as timely evaluation of accumulated data by qualified persons, which can reduce the extent or frequency of site monitoring [1] |
| Monitoring plan | Plan expected, scope tied to the protocol | Tailored to identified risks to participant safety and data reliability, describing each party's activities and tools [1] |
| Processes outside sites | Limited explicit coverage | Critical processes such as central imaging and central laboratories should be addressed in the plan [1] |
| Remote access | Source data verification mainly performed on site | Remote, secure, read-only access to source records is recognised [1] |
| Decentralised settings | Limited coverage | The monitoring approach should consider decentralised settings [1] |
The most significant conceptual shift is that R3 asks the sponsor to decide what needs monitoring, rather than defaulting to full source data verification at every site. Monitoring focus and frequency are expected to be adjusted as knowledge accumulates during the trial [1].
When does E6(R3) apply?
E6(R3) applies to clinical trials conducted under ICH good clinical practice, in the same way that E6(R2) did. Adoption is a regional matter: each regulator sets its own effective date and transition approach, so confirm the timeline that applies to your jurisdiction, whether EU, US, UK, Canada, Middle East or India.
Ongoing studies need a documented transition decision. Sponsors usually record whether a trial continues under the protocol and SOPs already in place or moves to R3 requirements through an amendment, and this should be agreed with the sponsor before monitors change their approach.
E6(R3) does not replace pharmacovigilance reporting rules. For electronic individual case safety reports, EMA GVP Module VI expects ICH-E2B(R3) formats to be used alongside the transition from R2, with MedDRA at the lowest level term [2]. For example, the Worldwide Unique Case Identification Number is data element C.1.8.1 in E2B(R3), where E2B(R2) used A.1.10.1 [2]. The E2B(R3) data element specifications are the harmonised validation rules for outbound ICSR XML messages [3].
What does it mean for monitors and sites?
For monitors, R3 means the monitoring plan becomes the central document that justifies every visit, remote review and central check. Monitoring should be performed by persons not involved in the clinical conduct of the trial at the site being monitored [1]. Sites should expect a mix of on-site visits, remote review and central data queries, and should keep source records ready for secure remote access where the sponsor's plan uses it.
Consider a hypothetical multi-site oncology trial where the sponsor wants to focus effort on the primary endpoint and safety data. A practical sequence looks like this:
- Identify critical data and processes, such as imaging assessments, safety laboratory results and informed consent records, as the monitoring plan must reflect identified risks [1].
- Write a risk-based monitoring plan that names the methods, tools, roles and rationale for on-site, remote and centralised activities [1].
- Run centralised review of accumulated data to flag a site with missing laboratory values or unusual enrolment, without a visit [1].
- Schedule a targeted visit to the flagged site, verifying critical data against source, using remote read-only access where it is permitted [1].
- Record the findings, adjust monitoring frequency using what was learned, and document the decision [1].
For sites, the practical change is that the investigator and staff should understand which data the sponsor treats as critical, because monitoring effort will concentrate there. Data protection and confidentiality duties apply to everyone handling trial data, including remote monitors [1].
Key takeaways
- ICH E6(R3) keeps R2's ethical and quality foundations but adds explicit risk-based, fit-for-purpose monitoring.
- Monitoring may combine on-site, remote and centralised methods, and the plan must reflect identified risks [1].
- Remote, secure, read-only access to source records is recognised, and decentralised settings must be considered [1].
- Adoption dates are set by each regulator, so check the timeline for your jurisdiction.
- ICSR reporting continues under GVP Module VI and ICH-E2B(R3) formats, which are separate from GCP [2][3].
- Training and SOPs built on R2 should be updated to cover R3 concepts, as part of any ich gcp training programme.
Build These Skills Now
Programs from ZANE ProEd Academy that directly address the skill gaps discussed above.
Where can I practise risk-based monitoring?
Reading the R3 text is only the first step, since the role depends on writing monitoring plans and making risk-based decisions. The ICH GCP Certificate from ZANE ProEd is an intermediate course in which learners work with essential document management in an eTMF simulator, source data verification in an EDC workbench and ALCOA+ audit checklists.
Frequently asked questions
Does E6(R3) replace E6(R2) immediately?
No. Each regulator sets its own effective date and transition approach, so the applicable version depends on the jurisdiction and the status of each trial.
Is centralised monitoring mandatory under R3?
Not as a single fixed method. Monitoring may include site monitoring and centralised monitoring, and the sponsor chooses the mix based on identified risks [1].
Does E6(R3) change ICSR reporting rules?
No. ICSR formats and content are governed by E2B(R3) and EMA GVP Module VI, which operate separately from GCP guidance [2][3].
Should ICH GCP training be updated after R3?
Yes. Training that still reflects R2 may omit risk-based monitoring, centralised review and remote access, so course content and SOPs should be revised to match the version your organisation follows.
Sources
- ICH E6(R3): Guideline for Good Clinical Practice (R3, Step 4 (2025)). ICH.
- EMA Good Pharmacovigilance Practices (GVP) Module VI: Collection, management and submission of reports of suspected adverse reactions (Rev 2). EMA.
- ICH E2B(R3): Electronic Transmission of Individual Case Safety Reports (ICSRs): Data Elements and Message Specification (R3). ICH.
Build These Skills Now
Programs from ZANE ProEd Academy that directly address the skill gaps discussed above.
Follow Zane ProEd on Google
Preferred SourceAdd our publication as a preferred source to get the latest clinical research guides, industry updates, and career intel directly in your Google Top Stories & AI Overviews.